Jyong Biotech Ltd(MENS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.06 | Insider Own | 62.2% | Shs Outstand | 74.2M | Perf Week | 8.47% |
| Market Cap | 0.15B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 28.1M | Perf Month | 0.99% |
| Enterprise Value | 0.17B | PEG | - | EPS next Q | - | Inst Own | 0.69% | Short Float | 0.76% | Perf Quarter | -8.07% |
| Income | -0.00B | P/S | - | EPS this Y | - | Inst Trans | 5.09% | Short Ratio | 4.8 | Perf Half Y | -5.96% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -34.42% | Short Interest | 0.21M | Perf YTD | -48.1% |
| Book/sh | -0.34 | P/C | 128.97 | EPS past 3/5Y | 11.59% -2.18% | ROE | - | 52W High | -96.06% ($52.01) | Perf Year | -94.9% |
| Cash/sh | 0.02 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 43.36% ($1.43) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -56.02% | Gross Margin | - | Volatility(W/M) | 13.47% 8.7% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.18 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.45 | EPS Q/Q | -102.19% | Profit Margin | - | RSI (14) | 53.62 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.45 | Sales Q/Q | - | SMA20 | 3.88% ($1.97) | Beta | 2.42 | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -1.67% ($2.08) | Rel Volume | 0.32 | Prev Close | $1.91 |
| Employees | 27 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -5.55% ($2.17) | Avg Volume(3M) | 0.04M | Price | $2.05 |
| IPO | 2025/6/17 | Option/Short | Yes/Yes | Trades | 158 | Volume | 14,162 | Change | 7.33% |
🧬 Ginkgo BioTech (MENS) is a plant-derived drug development company headquartered in New Taipei City, Taiwan. It focuses on developing therapeutics for urological diseases and is advancing clinical-stage candidates targeting benign prostatic hyperplasia (BPH), prostate cancer, and interstitial cystitis. The company is pursuing clinical development alongside a regulatory approval strategy aimed at the U.S., European Union, and Asian markets.
Over the past 1 year, on the lower side
96% below its 1-year high.
Traded less than usual. That is 32% of its average volume.
MENS has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #328 of 594 in the industry
Based on market cap of $152M.
MGNX#325 Macrogenics Inc $157M PER - 
STRO#326 Sutro Biopharma Inc $154M PER - 
CUE#327 Cue Biopharma Inc $154M PER - MENS#328 Jyong Biotech Ltd $152M PER - 
TARA#329 Protara Therapeutics Inc $147M PER - 
FAQ
What kind of company is MENS?
MENS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MENS?
The market cap of MENS is approximately $152M, ranking 4,226 within its sector.
What is the 52-week high and low for MENS?
MENS has recorded a 52-week high of $52.01 and a low of $1.43.
